vs
Cytek Biosciences, Inc.（CTKB）与EyePoint, Inc.（EYPT）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是EyePoint, Inc.的100.4倍（$62.1M vs $619.0K）。Cytek Biosciences, Inc.净利率更高（-70.9% vs -10922.3%，领先10851.4%）。Cytek Biosciences, Inc.同比增速更快（8.1% vs -94.7%）。Cytek Biosciences, Inc.自由现金流更多（$-1.8M vs $-66.0M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -77.0%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
CTKB vs EYPT — 直观对比
营收规模更大
CTKB
是对方的100.4倍
$619.0K
营收增速更快
CTKB
高出102.8%
-94.7%
净利率更高
CTKB
高出10851.4%
-10922.3%
自由现金流更多
CTKB
多$64.3M
$-66.0M
两年增速更快
CTKB
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $619.0K |
| 净利润 | $-44.1M | $-67.6M |
| 毛利率 | 52.9% | — |
| 营业利润率 | -9.0% | -11364.3% |
| 净利率 | -70.9% | -10922.3% |
| 营收同比 | 8.1% | -94.7% |
| 净利润同比 | -557.1% | -63.3% |
| 每股收益（稀释后） | — | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBEYPT
| Q4 25 | $62.1M | $619.0K | ||
| Q3 25 | $52.3M | $966.0K | ||
| Q2 25 | $45.6M | $5.3M | ||
| Q1 25 | $41.5M | $24.5M | ||
| Q4 24 | $57.5M | $11.6M | ||
| Q3 24 | $51.5M | $10.5M | ||
| Q2 24 | $46.6M | $9.5M | ||
| Q1 24 | $44.9M | $11.7M |
净利润CTKBEYPT
| Q4 25 | $-44.1M | $-67.6M | ||
| Q3 25 | $-5.5M | $-59.7M | ||
| Q2 25 | $-5.6M | $-59.4M | ||
| Q1 25 | $-11.4M | $-45.2M | ||
| Q4 24 | $9.6M | $-41.4M | ||
| Q3 24 | $941.0K | $-29.4M | ||
| Q2 24 | $-10.4M | $-30.8M | ||
| Q1 24 | $-6.2M | $-29.3M |
毛利率CTKBEYPT
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | 93.0% | ||
| Q2 24 | 54.6% | 85.2% | ||
| Q1 24 | 51.3% | 93.5% |
营业利润率CTKBEYPT
| Q4 25 | -9.0% | -11364.3% | ||
| Q3 25 | -17.6% | -6420.8% | ||
| Q2 25 | -23.3% | -1166.8% | ||
| Q1 25 | -36.1% | -199.7% | ||
| Q4 24 | 5.2% | -390.4% | ||
| Q3 24 | -8.2% | -311.2% | ||
| Q2 24 | -18.3% | -364.5% | ||
| Q1 24 | -23.9% | -285.2% |
净利率CTKBEYPT
| Q4 25 | -70.9% | -10922.3% | ||
| Q3 25 | -10.5% | -6183.4% | ||
| Q2 25 | -12.2% | -1114.3% | ||
| Q1 25 | -27.5% | -184.8% | ||
| Q4 24 | 16.8% | -357.3% | ||
| Q3 24 | 1.8% | -279.0% | ||
| Q2 24 | -22.4% | -325.3% | ||
| Q1 24 | -13.8% | -250.6% |
每股收益（稀释后）CTKBEYPT
| Q4 25 | — | $-0.82 | ||
| Q3 25 | — | $-0.85 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-0.65 | ||
| Q4 24 | — | $-0.65 | ||
| Q3 24 | — | $-0.54 | ||
| Q2 24 | — | $-0.58 | ||
| Q1 24 | — | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $306.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $306.1M |
| 总资产 | $461.5M | $364.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBEYPT
| Q4 25 | $90.9M | $306.1M | ||
| Q3 25 | $93.3M | $204.0M | ||
| Q2 25 | $75.5M | $255.7M | ||
| Q1 25 | $95.3M | $318.2M | ||
| Q4 24 | $98.7M | $370.9M | ||
| Q3 24 | $162.3M | $253.8M | ||
| Q2 24 | $177.9M | $280.2M | ||
| Q1 24 | $168.8M | $299.3M |
股东权益CTKBEYPT
| Q4 25 | $341.7M | $306.1M | ||
| Q3 25 | $378.6M | $200.2M | ||
| Q2 25 | $377.6M | $246.0M | ||
| Q1 25 | $379.6M | $298.4M | ||
| Q4 24 | $395.7M | $336.5M | ||
| Q3 24 | $385.5M | $218.7M | ||
| Q2 24 | $389.1M | $228.3M | ||
| Q1 24 | $392.6M | $249.9M |
总资产CTKBEYPT
| Q4 25 | $461.5M | $364.0M | ||
| Q3 25 | $494.9M | $251.7M | ||
| Q2 25 | $493.3M | $301.1M | ||
| Q1 25 | $482.6M | $362.6M | ||
| Q4 24 | $499.5M | $418.5M | ||
| Q3 24 | $491.2M | $300.9M | ||
| Q2 24 | $483.7M | $324.2M | ||
| Q1 24 | $492.1M | $329.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $-65.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-66.0M |
| 自由现金流率自由现金流/营收 | -2.9% | -10667.7% |
| 资本支出强度资本支出/营收 | 1.6% | 159.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $-243.4M |
8季度趋势，按日历期对齐
经营现金流CTKBEYPT
| Q4 25 | $-771.0K | $-65.0M | ||
| Q3 25 | $-3.9M | $-59.4M | ||
| Q2 25 | $108.0K | $-62.6M | ||
| Q1 25 | $-125.0K | $-53.1M | ||
| Q4 24 | $2.0M | $-35.8M | ||
| Q3 24 | $13.2M | $-39.0M | ||
| Q2 24 | $6.2M | $-20.2M | ||
| Q1 24 | $4.0M | $-31.2M |
自由现金流CTKBEYPT
| Q4 25 | $-1.8M | $-66.0M | ||
| Q3 25 | $-4.6M | $-60.2M | ||
| Q2 25 | $-1.5M | $-63.8M | ||
| Q1 25 | $-974.0K | $-53.4M | ||
| Q4 24 | $1.1M | $-36.2M | ||
| Q3 24 | $12.2M | $-40.6M | ||
| Q2 24 | $5.2M | $-21.1M | ||
| Q1 24 | $3.4M | $-32.4M |
自由现金流率CTKBEYPT
| Q4 25 | -2.9% | -10667.7% | ||
| Q3 25 | -8.7% | -6226.9% | ||
| Q2 25 | -3.2% | -1196.5% | ||
| Q1 25 | -2.3% | -218.4% | ||
| Q4 24 | 1.9% | -312.7% | ||
| Q3 24 | 23.7% | -385.8% | ||
| Q2 24 | 11.0% | -222.4% | ||
| Q1 24 | 7.6% | -277.0% |
资本支出强度CTKBEYPT
| Q4 25 | 1.6% | 159.3% | ||
| Q3 25 | 1.3% | 82.6% | ||
| Q2 25 | 3.5% | 22.9% | ||
| Q1 25 | 2.0% | 1.1% | ||
| Q4 24 | 1.6% | 3.3% | ||
| Q3 24 | 2.0% | 15.0% | ||
| Q2 24 | 2.3% | 9.5% | ||
| Q1 24 | 1.3% | 10.2% |
现金转化率CTKBEYPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
EYPT
暂无分部数据
